AstraZeneca and Daiichi Sankyo’s breast cancer drug Enhertu to join China’s state health insurance in 2025, enhancing ...
Current global health developments include China's green light for foreign-owned hospitals, the addition of AstraZeneca's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback